Gland Pharma Limited (GLAND.BO)
INR 1762.35
(-0.09%)
INR 1762.35
(-0.09%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 16.55 Billion INR | -14.91% |
| 2022 | 19.45 Billion INR | 64.07% |
| 2021 | 11.85 Billion INR | -7.02% |
| 2020 | 12.75 Billion INR | 68.61% |
| 2019 | 7.56 Billion INR | -17.06% |
| 2018 | 9.11 Billion INR | 77.81% |
| 2017 | 5.12 Billion INR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 15.77 Billion INR | 0.0% |
| 2023 Q2 | 20.84 Billion INR | 0.0% |
| 2023 FY | 16.55 Billion INR | -14.91% |
| 2023 Q4 | 16.55 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q4 | 19.45 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 FY | 19.45 Billion INR | 64.07% |
| 2022 Q2 | 15.59 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 14.6 Billion INR | 0.0% |
| 2021 FY | 11.85 Billion INR | -7.02% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q4 | 11.85 Billion INR | 0.0% |
| 2020 Q4 | 12.75 Billion INR | 0.0% |
| 2020 Q1 | 10.08 Billion INR | 33.41% |
| 2020 FY | 12.75 Billion INR | 68.61% |
| 2019 FY | 7.56 Billion INR | -17.06% |
| 2019 Q4 | 7.56 Billion INR | 0.0% |
| 2018 FY | 9.11 Billion INR | 77.81% |
| 2017 FY | 5.12 Billion INR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Abbott India Limited | 6.19 Billion INR | -167.155% |
| Cipla Limited | 52.37 Billion INR | 68.399% |
| GlaxoSmithKline Pharmaceuticals Limited | 5.33 Billion INR | -210.021% |
| Kopran Limited | 1.38 Billion INR | -1095.235% |
| Marksans Pharma Limited | 6.17 Billion INR | -167.862% |
| NGL Fine-Chem Limited | 433.03 Million INR | -3722.418% |
| Pfizer Limited | 4.33 Billion INR | -281.664% |
| Sanofi India Limited | 6.63 Billion INR | -149.358% |
| SMS Pharmaceuticals Limited | 2.33 Billion INR | -608.281% |